Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9527010.26442/20751753.2019.12.190724Review ArticleANTIARRHYTHMIC MEDICATION PROPAFENONE: PLACE IN CLINICAL PRACTICE (REVIEW)SyrovAndrei V.syrman2002_1@yahoo.comPavlovaTatiana V.-People’s Friendship University of RussiaConsultative and Diagnostic Center №6Samara State Medical UniversitySamara Regional Clinical Cardiology Dispensary15122019211211211728122021Copyright © 2019, Consilium Medicum2019Currently, antiarrhythmic drugs are widely used in clinical practice, influencing the clinical manifestations of arrhythmias, which can significantly improve the quality of life of patients. A key issue in antiarrhythmic therapy is ensuring the safety of treatment. Propafenone stands out among all antiarrhythmic drugs by the presence of a large evidence base obtained in various groups of patients, efficacy and safety, as well as the availability of both oral and intravenous forms of administration. In patients without a pronounced organic lesion of the heart, propafenone is the drug of choice in a large number of clinical situations: extrasystole, supraventricular tachycardia, atrial fibrillation and atrial flutter, and even certain types of ventricular tachycardia.antiarrhythmic therapyantiarrhythmic drugspropafenoneантиаритмическая терапияантиаритмические препаратыпропафенон[Zulkifly H, Lip G, Lane D. Epidemiology of atrial fibrillation. Int J Clin Pract 2018; 72 (3): 13070. DOI: 10.1111/ijcp.13070][Pistoia F, Sacco S, Tiseo C et al. The epidemiology of atrial fibrillation and stroke. Cardiol Clin 2016; 34 (2): 255-68.][Наджелудочковые нарушения сердечного ритма у взрослых. Клинические рекомендации. Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и электростимуляции, Общество специалистов по неотложной кардиологии. 2016 г.][2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.][2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC).][Диагностика и лечение фибрилляции предсердий. Клинические рекомендации. Всероссийского научного общества специалистов по клинической электрофизиологии, Аритмологии и электрокардиостимуляции (ВНОА) в сотрудничестве с Российским кардиологическим обществом (РКО) и Ассоциации сердечно-сосудистых хирургов России (АССХ). 2017 г.][2015 ACC/AHA/HRS Guideline for the Management of Adult Patients with Supraventricular Tachycardia. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.][2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.][9. RXlist amiodarone.][10. RXlist sotalol.][11. RXlist propaphenone.][Фомина И.Г., Тарзиманова А.И., Вертлужский А.В. и др. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий. «ПРОМЕТЕЙ» - открытое, мультицентровое, пилотное исследование в Российской Федерации. Кардиоваскулярная терапия и профилактика. 2005; 4 (4): 66-9.][Andre Ng G. Treating patients with ventricular ectopic beats. Heart 2006; 92 (11): 1707-12.][Kennedy HL, Whitlock JA, Sprague MK et al. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med 1985; 312 (4): 193-7.][Kostis J. The prognostic significance of ventricular ectopic activity. Am J Cardiol 1992; 70: 807-8.][Kostis J, McCrone K, Moreyra AE et al. Premature ventricular complexes in the absence of identifiable heart disease. Circulation 1981; 63: 1351-6.][Morshedi-Meibodi A, Evans JC, Levy D et al. Clinical correlates and prognostic significance of exercise-induced ventricular premature beats in the community: the Framingham Heart Study. Circulation 2004; 109 (20): 2417-22.][Niwano S, Wakisaka Y Niwano H et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart 2009; 95: 1230-7.][Jouven X, Zureik M, Desnos M et al. Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations. N Engl J Med 2000; 34 (3): 826-33.][DeBacker G, Jacobs D, Prineas R et al. Ventricular premature contractions: a randomized nondrug intervention trial in normal men. Circulation 1979; 59: 762-9.][Glatter KA, Myers R, Chiamvimonvat N. Recommendations regarding dietary intake and caffeine and alcohol consumption in patients with cardiac arrhythmias: what do you tell your patients to do or not to do? Curr Treat Options Cardiovasc Med 2012; 14: 529-35.][Myers MG. Caffeine and cardiac arrhythmias. Ann Intern Med 1991; 114 (2): 147-50.][Al-Khatib S, Allen LaPointe N, Chatterjee R et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 2014; 160 (11): 760-73.][Carlsson J, Miketic S, Windeler J et al. STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41 (10): 1690-6.][Chatterjee S, Sardar P, Lichstein E et al. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. PACE 2013; 36 (1): 122-33.][Hohnloser S, Kuck K, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356 (9244): 1789-94.][Olshansky B, Rosenfeld LE, Warner AL et al. AFFIRM Investigators The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004; 43 (7): 1201-8.][Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-77.][Caldeira D, David C, Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis 2012; 105 (4): 226-38.][Sethi N, Safi S, Nielsen E et al. The effects of rhythm control strategiesversus rate control strategies for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. System Rev 2017; 6: 47. DOI 10.1186/s13643-017-0449-z][Van Gelder I, Hagens V, Kingma J et al. Rate control versus electrical cardioversion for atrial fibrillation. A randomised comparison of two treatment strategies concerning morbidity, mortality, quality of life and cost-benefit - the RACE study design. Neth Heart J 2002; 10 (3): 118-4.][Оганов Р.Г., Симаненков В.И., Бакулин И.Г., Сыров А.В. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2019; 1: 5-66. [Oganov R.G., Simanenkov V.I., Bakulin I.G., Syrov A.V. Komorbidnaia patologiia v klinicheskoi praktike. Algoritmy diagnostiki i lecheniia. Klinicheskie rekomendatsii. Kardiovaskuliarnaia terapiia i profilaktika. 2019; 1: 5-66 (in Russian).]][Alboni P, Botto GL, Baldi N et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004; 351 (23): 2384-91.][Meinertz T, Lip GY, Lombardi F et al. ERAFT Investigators. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol 2002; 90 (12): 1300-6.][Porterfield J, Porterfield L.Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol 1989; 63 (1): 114-6. Am J Cardiol 2004; 94 (5): 663-5.][Antonelli D, Darawsha A, Rimbrot S et al. Propafenone dose for emergency room conversion of paroxysmal atrial fibrillation. Harefuah 1999; 136 (11): 857-9.][Azpitarte J, Alvarez M, Baun O et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J 1997; 18 (10): 1649-54.][Boriani G, Biffi M, Capucci A et al. Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation. Pacing Clin Electrophysiol 1998; 21 (11 Pt 2): 2465-9.][Boriani G, Martignani C, Biffi M et al. Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment. Drugs 2002; 62 (3): 415 23.][Blanc J, Voinov C, Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol 1999; 84 (9): 1029-32.][Botto G, Capucci A, Bonini W et al. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. Int J Cardiol 1997; 58 (1): 55-61.][Capucci A, Villani GQ, Aschieri D, Piepoli M. Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study. Int J Cardiol 1999; 68 (2): 187-96. Erratum in: Int J Cardiol 1999; 70 (2): 213.][Martignani C, Diemberger I, Ziacchi M et al. Oral loading of propafenone: restoring its role before restoring rhythm. Europace 2017; 19 (11): 1903.][Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001; 37 (2): 542-7.][Hughes C, Sunderji R, Gin K. Oral propafenone for rapid conversion of recent onset atrial fibrillation - a review. Can J Cardiol 1997; 13 (9): 839-42.][Antonelli D, Freedberg NA, Feldman A et al. Intravenous propafenone for conversion of atrial fibrillation in the emergency room. Harefuah 2004; 143 (7): 471-4.][Boriani G, Capucci A, Lenzi T et al. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest 1995; 108 (2): 355-8.][Capucci A, Boriani G. Intravenous administration of propafenone. J Am Coll Cardiol 1992; 19 (6): 1368-9.][Cointe R, Metge M, Bru P, et al. Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation. Ann Cardiol Angeiol (Paris) 1993; 42 (4): 223-7.][Carerj S, Cavalli G, Magazu A et al. Treatment of recent atrial fibrillation with intravenous propafenone. Cardiologia 1989; 34 (1): 83-5.][Goy J, Metrailler J, Humair L, de Torrente A. Restoration of sinus rhythm in atrial fibrillation of recent onset using intravenous propafenone. Am Heart J 1991; 122 (6): 1788-90.][Haefeli EW, Vozeh S, Ha HR, Follath F Comparison of the pharmacodynamic effects of intravenous and oral propafenone. Clin Pharmacol Ther 1990; 48 (3): 245-54.][Liguori A, di Ieso N, D'Armiento F et al. Intravenous propafenone for suppression of symptomatic atrial fibrillation and atrial flutter in a first aid hospital. Riv Eur Sci Med Farmacol 1992; 14 (4): 229-32.][Madonia S, De Simone M, Brai G et al. Intravenous versus oral initial load of propafenone for conversion of recent-onset atrial fibrillation in the emergency room: a randomized trial. Ital Heart J 2000; 1 (7): 475-9.][Margheri M, Fradella G, Maioli M et al. Efficacy of intravenous and per os propafenone in the ambulatory treatment of recent-onset atrial fibrillation. G Ital Cardiol 1992; 22 (3): 257-65.][Velazquez Rodriguez E, Cancino Rodriguez C, Arias Estrada S,et al. Pharmacological cardioversion with intravenous propafenone in atrial fibrillation. Arch Inst Cardiol Mex 2000; 70 (2): 160-6.][Zadura M, Grossmann G, Modrzewska A et al. Comparison of efficacy, safety and cost-effectiveness of intravenous versus oral propafenone in paroxysmal atrial fibrillation. Pol Merkur Lekarski 2001; 11 (62): 137-9.][Antman EM, Beamer AD, Cantillon C et al. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988; 12 (4): 1005-11.][Kowey PR, Yannicelli D, Amsterdam E; COPPA-II Investigators. Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2004; 94 (5): 663-5.][Лукьянова И.Ю., Кузнецов А.В., Комарницкий В.М., Козырева А.Г. Изучение эффективности и безопасности препаратов для медикаментозной кардиоверсии у больных с пароксизмальной формой фибрилляции предсердий на догоспитальном этапе. Скорая медицинская помощь. 2017; 4: 43-7.][Миллер О.Н., Старичков С.А., Поздняков и др. Эффективность и безопасность применения пропафенона (пропанорма®) и амиодарона (кордарона®) у больных с фибрилляцией предсердий на фоне АГ, ИБС и ХСН с сохраненной систолической функцией ЛЖ. Многоцентровое открытое рандомизированное, проспективное, сравнительное исследование ПРОСТОР. Рос. кардиологический журн. 2010; 4: 56-72.][Тарасов А.В., Косых С.А., Бушуева Е.В. и др. Сравнение эффективности инъекционных форм антиаритмических препаратов пропафенона и амиодарона при проведении фармакологической кардиоверсии пароксизмальной фибрилляции предсердий. Consilium Medi-cum. 2019; 1: 81-6.][Lafuente-Lafuente C, Longas-Tejero MA, Bergmann J, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012; 5: CD005049.][Клинические рекомендации «Желудочковые аритмии». ФГБУ «ННПЦССХ им. А.Н.Бакуле-ва». Центр хирургической и интервенционной аритмологии. М., 2017. @@Clinical recommendations "Ventricular arrhythmias". Bakulev National Medical Research Center for Cardiovascular Surgery. Center for Surgical and Interventional Arrhythmology Moscow, 2017 (in Russian).][Клинические рекомендации по диагностике и лечению нарушений ритма сердца и проводимости. Общество специалистов по неотложной кардиологии, 2013. @@Klinicheskie rekomendatsii po diagnostike i lecheniiu narushenii ritma serdtsa i provodimosti. Ob-shchestvo spetsialistov po neotlozhnoi kardiologii, 2013 (in Russian).][Iwai S, Lerman BB. Management of ventricular tachycardia in patients with clinically normal hearts. Curr Cardiol Rep 2000; 2: 515-21.][Bigger JT Jr, Dresdale FJ, Heissenbuttel RH et al. Ventricular arrhythmias in ischemic heart disease: mechanism, prevalence, significance, and management. Prog Cardiovasc Dis 1977; 19: 255-300.][Eldar M, Sievner Z, Goldbourt U et al. Primary ventricular tachycardia in acute myocardial infarction: clinical characteristics and mortality. The SPRINT Study Group. Ann Intern Med 1992; 117: 31-6.][Ng E, Adlam D, Keal RP et al. Recurrent ventricular tachycardia of non-ischaemic origin. J Royal Soc Med 2004; 97 (1): 23-5.][Bardy G, Lee K, Mark D et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352 (3): 225-37.]